{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T00:31:14Z","timestamp":1715646674458},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T00:00:00Z","timestamp":1713225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T00:00:00Z","timestamp":1713225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Although lomustine has been used as a chemotherapeutic agent for decades, no recommendation on appropriate chemotherapy-induced nausea and vomiting (CINV) prophylaxis is available. As CINV is considered one of the most bothersome side effects of chemotherapy, adequate prophylaxis is of relevance to improve quality of life during cancer treatment. The aim of this retrospective case series was to report the incidence and severity of CINV in pediatric patients with high-grade glioma treated with lomustine and to formulate recommendations for appropriate CINV prophylaxis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Pediatric patients treated with lomustine for high-grade glioma according to the ACNS 0423 protocol were identified retrospectively. Two researchers independently reviewed and classified complaints of CINV and administered CINV prophylaxis. Treatment details, tumor localization, and response to therapy were systematically extracted from the patients\u2019 files.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Seventeen children aged 8\u201318\u00a0years received a median of four cycles of lomustine. CINV complaints and administered prophylaxis were evaluable in all patients. Moderate or severe CINV was observed in 13\/17 (76%) patients. Administered prophylactic CINV regimens varied from no prophylaxis to triple-agent combinations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In this case series, we identified lomustine as a highly emetogenic chemotherapeutic agent. According to the current guidelines, CINV prophylaxis with a 5-HT3 receptor antagonist in combination with dexamethasone and (fos)aprepitant is recommended.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00520-024-08474-7","type":"journal-article","created":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T17:01:47Z","timestamp":1713286907000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of chemotherapy-induced nausea and vomiting in pediatric patients with high-grade glioma treated with lomustine\u2014a case series"],"prefix":"10.1007","volume":"32","author":[{"given":"Kim P. J.","family":"Schellekens","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah Babette","family":"Hageman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Els C.","family":"Haverkate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne D.","family":"van de Wetering","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederike K.","family":"Engels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aeltsje","family":"Brinksma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelien","family":"de Vos-Kerkhof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,16]]},"reference":[{"key":"8474_CR1","unstructured":"(2022) Summary of product characteristics - Lomustine.\u00a0https:\/\/www.medac.eu\/fileadmin\/user_upload\/medac-eu\/SPCs\/common_SPCs\/Lomustine_medac-spc-common.pdf"},{"key":"8474_CR2","unstructured":"FDA (2016) Highlights of prescribing information - Gleostine (Lomustine) capsules.\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/017588s042lbl.pdf"},{"issue":"20","key":"8474_CR3","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1056\/NEJMra2116344","volume":"386","author":"AR Cohen","year":"2022","unstructured":"Cohen AR (2022) Brain tumors in children. N Engl J Med 386(20):1922\u20131931. https:\/\/doi.org\/10.1056\/NEJMra2116344","journal-title":"N Engl J Med"},{"issue":"10","key":"8474_CR4","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1093\/neuonc\/now038","volume":"18","author":"RI Jakacki","year":"2016","unstructured":"Jakacki RI et al (2016) Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children\u2019s Oncology Group ACNS0423 study. Neuro Oncol 18(10):1442\u20131450. https:\/\/doi.org\/10.1093\/neuonc\/now038","journal-title":"Neuro Oncol"},{"issue":"10","key":"8474_CR5","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1007\/s00520-005-0803-x","volume":"13","author":"N Neymark","year":"2005","unstructured":"Neymark N, Crott R (2005) Impact of emesis on clinical and economic outcomes of cancer therapy with highly emetogenic chemotherapy regimens: a retrospective analysis of three clinical trials. Supp Care Cancer 13(10):812\u2013818. https:\/\/doi.org\/10.1007\/s00520-005-0803-x","journal-title":"Supp Care Cancer"},{"issue":"9","key":"8474_CR6","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1038\/bmt.2017.112","volume":"52","author":"J Flank","year":"2017","unstructured":"Flank J et al (2017) The burden of chemotherapy-induced nausea and vomiting in children receiving hematopoietic stem cell transplantation conditioning: a prospective study. Bone Marrow Transplant 52(9):1294\u20131299. https:\/\/doi.org\/10.1038\/bmt.2017.112","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"8474_CR7","doi-asserted-by":"publisher","first-page":"e29329","DOI":"10.1002\/pbc.29329","volume":"69","author":"N Tang","year":"2022","unstructured":"Tang N et al (2022) Perceptions of parents of pediatric patients with acute lymphoblastic leukemia on oral chemotherapy administration: a qualitative analysis. Pediatr Blood Cancer 69(1):e29329\u2013e29329. https:\/\/doi.org\/10.1002\/pbc.29329","journal-title":"Pediatr Blood Cancer"},{"issue":"27","key":"8474_CR8","doi-asserted-by":"publisher","first-page":"4472","DOI":"10.1200\/JCO.2006.05.6382","volume":"24","author":"B Bloechl-Daum","year":"2006","unstructured":"Bloechl-Daum B et al (2006) Delayed nausea and vomiting continue to reduce patients\u2019 quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 24(27):4472\u20134478. https:\/\/doi.org\/10.1200\/JCO.2006.05.6382","journal-title":"J Clin Oncol"},{"key":"8474_CR9","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1477-7525-1-46","volume":"1","author":"E Ballatori","year":"2003","unstructured":"Ballatori E, Roila F (2003) Impact of nausea and vomiting on quality of life in cancer patients during chemotherapy. Health Qual Life Outcomes 1:46\u201346. https:\/\/doi.org\/10.1186\/1477-7525-1-46","journal-title":"Health Qual Life Outcomes"},{"issue":"28","key":"8474_CR10","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1200\/JCO.2017.74.4789","volume":"35","author":"PJ Hesketh","year":"2017","unstructured":"Hesketh PJ et al (2017) Antiemetics: American society of clinical oncology clinical practice guideline update. J Clin Oncol 35(28):3240\u20133261. https:\/\/doi.org\/10.1200\/JCO.2017.74.4789","journal-title":"J Clin Oncol"},{"issue":"suppl 5","key":"8474_CR11","doi-asserted-by":"publisher","first-page":"v119","DOI":"10.1093\/annonc\/mdw270","volume":"27","author":"F Roila","year":"2016","unstructured":"Roila F et al (2016) 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 27(suppl 5):v119\u2013v133. https:\/\/doi.org\/10.1093\/annonc\/mdw270","journal-title":"Ann Oncol"},{"key":"8474_CR12","doi-asserted-by":"publisher","unstructured":"Paw Cho Sing E et al (2019) Classification of the acute emetogenicity of chemotherapy in pediatric patients: a clinical practice guideline. Pediatric Blood Cancer 66(5):e27646\u2013e27646. https:\/\/doi.org\/10.1002\/pbc.27646.","DOI":"10.1002\/pbc.27646"},{"issue":"12","key":"8474_CR13","doi-asserted-by":"publisher","first-page":"e30001","DOI":"10.1002\/pbc.30001","volume":"69","author":"P Patel","year":"2022","unstructured":"Patel P et al (2022) Prevention of acute and delayed chemotherapy-induced nausea and vomiting in pediatric cancer patients: a clinical practice guideline. Pediatr Blood Cancer 69(12):e30001\u2013e30001. https:\/\/doi.org\/10.1002\/pbc.30001","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"8474_CR14","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1177\/0271678X19859847","volume":"39","author":"D Dubinski","year":"2019","unstructured":"Dubinski D et al (2019) Controversial roles for dexamethasone in glioblastoma - opportunities for novel vascular targeting therapies. J Cereb Blood Flow Metabol 39(8):1460\u20131468. https:\/\/doi.org\/10.1177\/0271678X19859847","journal-title":"J Cereb Blood Flow Metabol"},{"issue":"12","key":"8474_CR15","doi-asserted-by":"publisher","first-page":"e28716","DOI":"10.1002\/pbc.28716","volume":"67","author":"P Patel","year":"2020","unstructured":"Patel P et al (2020) Dexamethasone dosing for prevention of acute chemotherapy-induced vomiting in pediatric patients: a systematic review. Pediatr Blood Cancer 67(12):e28716\u2013e28716. https:\/\/doi.org\/10.1002\/pbc.28716","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"8474_CR16","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1093\/nop\/npu029","volume":"2","author":"P Roth","year":"2015","unstructured":"Roth P, Happold C, Weller M (2015) Corticosteroid use in neuro-oncology: an update. Neuro-oncol Pract 2(1):6\u201312. https:\/\/doi.org\/10.1093\/nop\/npu029","journal-title":"Neuro-oncol Pract"},{"issue":"3","key":"8474_CR17","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s00441-013-1762-z","volume":"355","author":"E Salvador","year":"2014","unstructured":"Salvador E, Shityakov S, F\u00f6rster C (2014) Glucocorticoids and endothelial cell barrier function. Cell Tissue Res 355(3):597\u2013605. https:\/\/doi.org\/10.1007\/s00441-013-1762-z","journal-title":"Cell Tissue Res"},{"issue":"4","key":"8474_CR18","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1215\/15228517-2008-019","volume":"10","author":"RI Jakacki","year":"2008","unstructured":"Jakacki RI et al (2008) A phase I trial of temozolomide and lomustine in newly diagnosed high-grade gliomas of childhood. Neuro Oncol 10(4):569\u2013576. https:\/\/doi.org\/10.1215\/15228517-2008-019","journal-title":"Neuro Oncol"},{"issue":"10172","key":"8474_CR19","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/s0140-6736(18)31791-4","volume":"393","author":"U Herrlinger","year":"2019","unstructured":"Herrlinger U et al (2019) Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG\/NOA-09): a randomised, open-label, phase 3 trial. Lancet 393(10172):678\u2013688. https:\/\/doi.org\/10.1016\/s0140-6736(18)31791-4","journal-title":"Lancet"},{"issue":"4","key":"8474_CR20","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S1470-2045(15)70061-6","volume":"16","author":"HJ Kang","year":"2015","unstructured":"Kang HJ et al (2015) Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomised, double-blind, phase 3 trial. Lancet Oncol 16(4):385\u2013394. https:\/\/doi.org\/10.1016\/S1470-2045(15)70061-6","journal-title":"Lancet Oncol"},{"issue":"22","key":"8474_CR21","doi-asserted-by":"publisher","first-page":"4112","DOI":"10.1200\/JCO.2003.01.095","volume":"21","author":"PJ Hesketh","year":"2003","unstructured":"Hesketh PJ et al (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin\u2013the Aprepitant Protocol 052 Study Group. J Clin Oncol 21(22):4112\u20134119. https:\/\/doi.org\/10.1200\/JCO.2003.01.095","journal-title":"J Clin Oncol"},{"issue":"12","key":"8474_CR22","doi-asserted-by":"publisher","first-page":"9991","DOI":"10.1007\/s00520-022-07423-6","volume":"30","author":"AL Nijstad","year":"2022","unstructured":"Nijstad AL et al (2022) Overestimation of the effect of (fos)aprepitant on intravenous dexamethasone pharmacokinetics requires adaptation of the guidelines for children with chemotherapy-induced nausea and vomiting. Support Care Cancer 30(12):9991\u20139999. https:\/\/doi.org\/10.1007\/s00520-022-07423-6","journal-title":"Support Care Cancer"},{"issue":"24","key":"8474_CR23","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1200\/jco.20.02730","volume":"39","author":"JM Michalski","year":"2021","unstructured":"Michalski JM et al (2021) Children\u2019s oncology group phase III trial of reduced-dose and reduced-volume radiotherapy with chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 39(24):2685\u20132697. https:\/\/doi.org\/10.1200\/jco.20.02730","journal-title":"J Clin Oncol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-08474-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-024-08474-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-08474-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T09:13:25Z","timestamp":1715591605000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-024-08474-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,16]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["8474"],"URL":"https:\/\/doi.org\/10.1007\/s00520-024-08474-7","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,16]]},"assertion":[{"value":"5 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data used in this retrospective study has been collected from patients who provided informed consent for the use of their clinical data (Biobank Princess M\u00e1xima Center). The Biobank protocols are in accordance with the ethical standards of our institution and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Financial interests: The authors declare they have no financial interests.Non-financial interests: Dr. Evelien de Vos-Kerkhof is an associate editor in <i>Supportive Care in Cancer<\/i>.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"290"}}